Platelet Lipidomic Profiling: Novel Insight into Cytosolic Phospholipase A<inf>2</inf>α Activity and Its Role in Human Platelet Activation

Matthew T. Duvernay, Anton Matafonov, Craig W. Lindsley, Heidi E. Hamm

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

With a newer, more selective and efficacious cytosolic phospholipase A<inf>2</inf>α (cPLA<inf>2</inf>α) inhibitor available, we revisited the role of cPLA<inf>2</inf>α activity in platelet activation and discovered that a component of platelet signaling, even larger than previously appreciated, relies on this enzyme. In a whole blood shear-based flow chamber assay, giripladib, a cPLA<inf>2</inf>α inhibitor, reduced platelet adhesion and accumulation on collagen. Moreover, giripladib differentially affected P-selectin expression and GPIIbIIIa activation depending on the agonist employed. While protease-activated receptor 1 (PAR1)-mediated platelet activation was unaffected by giripladib, the levels of PAR4- and GPVI-mediated platelet activation were significantly reduced. Meanwhile, the thromboxane A<inf>2</inf> receptor antagonist SQ29548 had no effect on PAR-, GPVI-, or puriniergic receptor-mediated platelet activation, suggesting that another eicosanoid produced downstream of arachidonic acid liberation by cPLA<inf>2</inf>α was responsible for this large component of PAR4- and GPVI-mediated platelet activation. In parallel, we profiled PAR-mediated changes in glycerophospholipid (GPL) mass with and without giripladib to better understand cPLA<inf>2</inf>α-mediated lipid metabolism. Phosphatidylcholine and phosphatidylethanolamine (PE) demonstrated the largest consumption of mass during thrombin stimulation. Additionally, we confirm phosphatidylinositol as a major substrate of cPLA<inf>2</inf>α. A comparison of PAR1- and PAR4-induced metabolism revealed the consumption of more putative arachidonyl-PE species downstream of PAR1 activation. Instead of enhanced cPLA<inf>2</inf>α activity and therefore more arachidonic acid liberation downstream of PAR4, these results indicate the major role that cPLA<inf>2</inf>α activity plays in platelet function and suggest that a novel eicosanoid is produced in response to platelet activation that represents a large component of PAR4- and GPVI-mediated responses.

Original languageEnglish
Pages (from-to)5578-5588
Number of pages11
JournalBiochemistry
Volume54
Issue number36
DOIs
Publication statusPublished - 15 Sep 2015
Externally publishedYes

Fingerprint

Cytosolic Phospholipases A2
Platelet Activation
Platelets
Blood Platelets
Chemical activation
PAR-1 Receptor
Eicosanoids
Arachidonic Acid
Prostaglandin H2 Receptors Thromboxane A2
Glycerophospholipids
P-Selectin
Phosphatidylinositols
Phosphatidylcholines
Lipid Metabolism
Thrombin
Collagen
Metabolism
PLA-695
Assays
Blood

ASJC Scopus subject areas

  • Biochemistry

Cite this

Platelet Lipidomic Profiling : Novel Insight into Cytosolic Phospholipase A<inf>2</inf>α Activity and Its Role in Human Platelet Activation. / Duvernay, Matthew T.; Matafonov, Anton; Lindsley, Craig W.; Hamm, Heidi E.

In: Biochemistry, Vol. 54, No. 36, 15.09.2015, p. 5578-5588.

Research output: Contribution to journalArticle

Duvernay, Matthew T. ; Matafonov, Anton ; Lindsley, Craig W. ; Hamm, Heidi E. / Platelet Lipidomic Profiling : Novel Insight into Cytosolic Phospholipase A<inf>2</inf>α Activity and Its Role in Human Platelet Activation. In: Biochemistry. 2015 ; Vol. 54, No. 36. pp. 5578-5588.
@article{23e739fbd90242b8913de0facaec0f71,
title = "Platelet Lipidomic Profiling: Novel Insight into Cytosolic Phospholipase A2α Activity and Its Role in Human Platelet Activation",
abstract = "With a newer, more selective and efficacious cytosolic phospholipase A2α (cPLA2α) inhibitor available, we revisited the role of cPLA2α activity in platelet activation and discovered that a component of platelet signaling, even larger than previously appreciated, relies on this enzyme. In a whole blood shear-based flow chamber assay, giripladib, a cPLA2α inhibitor, reduced platelet adhesion and accumulation on collagen. Moreover, giripladib differentially affected P-selectin expression and GPIIbIIIa activation depending on the agonist employed. While protease-activated receptor 1 (PAR1)-mediated platelet activation was unaffected by giripladib, the levels of PAR4- and GPVI-mediated platelet activation were significantly reduced. Meanwhile, the thromboxane A2 receptor antagonist SQ29548 had no effect on PAR-, GPVI-, or puriniergic receptor-mediated platelet activation, suggesting that another eicosanoid produced downstream of arachidonic acid liberation by cPLA2α was responsible for this large component of PAR4- and GPVI-mediated platelet activation. In parallel, we profiled PAR-mediated changes in glycerophospholipid (GPL) mass with and without giripladib to better understand cPLA2α-mediated lipid metabolism. Phosphatidylcholine and phosphatidylethanolamine (PE) demonstrated the largest consumption of mass during thrombin stimulation. Additionally, we confirm phosphatidylinositol as a major substrate of cPLA2α. A comparison of PAR1- and PAR4-induced metabolism revealed the consumption of more putative arachidonyl-PE species downstream of PAR1 activation. Instead of enhanced cPLA2α activity and therefore more arachidonic acid liberation downstream of PAR4, these results indicate the major role that cPLA2α activity plays in platelet function and suggest that a novel eicosanoid is produced in response to platelet activation that represents a large component of PAR4- and GPVI-mediated responses.",
author = "Duvernay, {Matthew T.} and Anton Matafonov and Lindsley, {Craig W.} and Hamm, {Heidi E.}",
year = "2015",
month = "9",
day = "15",
doi = "10.1021/acs.biochem.5b00549",
language = "English",
volume = "54",
pages = "5578--5588",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "36",

}

TY - JOUR

T1 - Platelet Lipidomic Profiling

T2 - Novel Insight into Cytosolic Phospholipase A2α Activity and Its Role in Human Platelet Activation

AU - Duvernay, Matthew T.

AU - Matafonov, Anton

AU - Lindsley, Craig W.

AU - Hamm, Heidi E.

PY - 2015/9/15

Y1 - 2015/9/15

N2 - With a newer, more selective and efficacious cytosolic phospholipase A2α (cPLA2α) inhibitor available, we revisited the role of cPLA2α activity in platelet activation and discovered that a component of platelet signaling, even larger than previously appreciated, relies on this enzyme. In a whole blood shear-based flow chamber assay, giripladib, a cPLA2α inhibitor, reduced platelet adhesion and accumulation on collagen. Moreover, giripladib differentially affected P-selectin expression and GPIIbIIIa activation depending on the agonist employed. While protease-activated receptor 1 (PAR1)-mediated platelet activation was unaffected by giripladib, the levels of PAR4- and GPVI-mediated platelet activation were significantly reduced. Meanwhile, the thromboxane A2 receptor antagonist SQ29548 had no effect on PAR-, GPVI-, or puriniergic receptor-mediated platelet activation, suggesting that another eicosanoid produced downstream of arachidonic acid liberation by cPLA2α was responsible for this large component of PAR4- and GPVI-mediated platelet activation. In parallel, we profiled PAR-mediated changes in glycerophospholipid (GPL) mass with and without giripladib to better understand cPLA2α-mediated lipid metabolism. Phosphatidylcholine and phosphatidylethanolamine (PE) demonstrated the largest consumption of mass during thrombin stimulation. Additionally, we confirm phosphatidylinositol as a major substrate of cPLA2α. A comparison of PAR1- and PAR4-induced metabolism revealed the consumption of more putative arachidonyl-PE species downstream of PAR1 activation. Instead of enhanced cPLA2α activity and therefore more arachidonic acid liberation downstream of PAR4, these results indicate the major role that cPLA2α activity plays in platelet function and suggest that a novel eicosanoid is produced in response to platelet activation that represents a large component of PAR4- and GPVI-mediated responses.

AB - With a newer, more selective and efficacious cytosolic phospholipase A2α (cPLA2α) inhibitor available, we revisited the role of cPLA2α activity in platelet activation and discovered that a component of platelet signaling, even larger than previously appreciated, relies on this enzyme. In a whole blood shear-based flow chamber assay, giripladib, a cPLA2α inhibitor, reduced platelet adhesion and accumulation on collagen. Moreover, giripladib differentially affected P-selectin expression and GPIIbIIIa activation depending on the agonist employed. While protease-activated receptor 1 (PAR1)-mediated platelet activation was unaffected by giripladib, the levels of PAR4- and GPVI-mediated platelet activation were significantly reduced. Meanwhile, the thromboxane A2 receptor antagonist SQ29548 had no effect on PAR-, GPVI-, or puriniergic receptor-mediated platelet activation, suggesting that another eicosanoid produced downstream of arachidonic acid liberation by cPLA2α was responsible for this large component of PAR4- and GPVI-mediated platelet activation. In parallel, we profiled PAR-mediated changes in glycerophospholipid (GPL) mass with and without giripladib to better understand cPLA2α-mediated lipid metabolism. Phosphatidylcholine and phosphatidylethanolamine (PE) demonstrated the largest consumption of mass during thrombin stimulation. Additionally, we confirm phosphatidylinositol as a major substrate of cPLA2α. A comparison of PAR1- and PAR4-induced metabolism revealed the consumption of more putative arachidonyl-PE species downstream of PAR1 activation. Instead of enhanced cPLA2α activity and therefore more arachidonic acid liberation downstream of PAR4, these results indicate the major role that cPLA2α activity plays in platelet function and suggest that a novel eicosanoid is produced in response to platelet activation that represents a large component of PAR4- and GPVI-mediated responses.

UR - http://www.scopus.com/inward/record.url?scp=84941686997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941686997&partnerID=8YFLogxK

U2 - 10.1021/acs.biochem.5b00549

DO - 10.1021/acs.biochem.5b00549

M3 - Article

C2 - 26295742

AN - SCOPUS:84941686997

VL - 54

SP - 5578

EP - 5588

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 36

ER -